[Federal Register Volume 84, Number 156 (Tuesday, August 13, 2019)]
[Notices]
[Page 40072]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2019-17244]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Office of the Director; Notice of Charter Renewal
In accordance with Title 41 of the U.S. Code of Federal
Regulations, Section 102-3.65(a), notice is hereby given that the
Charter for the Novel and Exceptional Technology and Research Advisory
Committee was renewed for an additional two-year period on June 30,
2019. Prior to this renewal, the Charter was amended to reflect the
Committee's name change from the Recombinant DNA Advisory Committee to
the Novel and Exceptional Technology and Research Advisory Committee.
It is determined that the Novel and Exceptional Technology and
Research Advisory Committee is in the public interest in connection
with the performance of duties imposed on the National Institutes of
Health by law, and that these duties can best be performed through the
advice and counsel of this group.
Inquiries may be directed to Claire Harris, Director, Office of
Federal Advisory Committee Policy, Office of the Director, National
Institutes of Health, 6701 Democracy Boulevard, Suite 1000, Bethesda,
Maryland 20892 (Mail code 4875), Telephone (301) 496-2123, or
[email protected].
Dated: August 7, 2019.
Ronald J. Livingston, Jr.,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2019-17244 Filed 8-12-19; 8:45 am]
BILLING CODE 4140-01-P